Kenichi Fujise
Medical Practice in Galveston, TX
License number
New Jersey 25MA05696400
Issued Date
Sep 17, 1991
Expiration Date
Jun 30, 2017
Category
Medical Examiners
Type
Medical Doctor
Address
Address
Galveston, TX
Organization information
See more information about Kenichi Fujise at bizstanding.comUniversity Of Texas Medical Branch - Kenichi Fujise MD
301 University Blvd #5106JSA, Galveston, TX 77555
Categories:
Cardiology Physicians & Surgeons
Phone:
(409) 772-4698 (Phone)
Professional information
Dr. Kenichi Fujise - MD (Doctor of Medicine)
Hospitals:
2240 Gulf Fwy S STE 2100, League City 77573
UTMB Cardiology
301 University Blvd, Galveston 77555
Memorial Hermann - Texas Medical Center
6411 Fannin St, Houston 77030
2240 Gulf Fwy S STE 2100, League City 77573
UTMB Cardiology
301 University Blvd, Galveston 77555
Memorial Hermann - Texas Medical Center
6411 Fannin St, Houston 77030
UTMB Cardiology
301 University Blvd, Galveston 77555
Memorial Hermann - Texas Medical Center
6411 Fannin St, Houston 77030
2240 Gulf Fwy S STE 2100, League City 77573
UTMB Cardiology
301 University Blvd, Galveston 77555
Memorial Hermann - Texas Medical Center
6411 Fannin St, Houston 77030
Education:
Medical Schools
Kyoto University, Faculty Of Medicine
Graduated: 1987
Kyoto University, Faculty Of Medicine
Graduated: 1987
Kenichi Fujise, Galveston TX
Specialties:
Cardiologist
Address:
301 University Blvd, Galveston, TX 77555
6410 Fannin St, Houston, TX 77030
6410 Fannin St, Houston, TX 77030
Education:
Kyoto University, Faculty of Medicine - Doctor of Medicine
Metropolitan Hospital Center - Residency - Internal Medicine
Metropolitan Hospital Center - Residency - Internal Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Cardiovascular Disease (Internal Medicine), American Board of Internal Medicine Sub-certificate in Interventional Cardiology (Internal Medicine)
Reducing Myocardial Reperfusion Injury By The Combination Therapy Of Protein Kinase A Activation And B1-Adrenergic Receptor Blockade
US Patent:
8415384, Apr 9, 2013
Filed:
Jun 12, 2009
Appl. No.:
12/997485
Inventors:
Kenichi Fujise - Galveston TX, US
Barry F. Uretsky - Fort Smith AR, US
Barry F. Uretsky - Fort Smith AR, US
Assignee:
The Board of Regents of the University of Texas System - Austin TX
International Classification:
A61K 31/44, A61K 31/675, A61K 31/135, A61P 9/10
US Classification:
514352, 514 94, 514651, 514824
Abstract:
Embodiments of the invention are directed to methods of treating reperfusion or resuscitation injury in an individual in need of such treatment, comprising the step of administering to the individual who has had, having, or is at immediate risk of having an ischemic event an amount of a composition comprising a protein kinase A (PKA) activator and a β-adrenergic receptor antagonist sufficient to reduce reperfusion injury to an ischemic tissue.
Uses Of Morelloflavone
US Patent:
2011021, Sep 8, 2011
Filed:
Jan 28, 2011
Appl. No.:
12/931310
Inventors:
Kenichi Fujise - Galveston TX, US
Nongporn Towatana - Hat Yai, TH
Wilawan Mahabusarakam - Songkhia, TH
Nongporn Towatana - Hat Yai, TH
Wilawan Mahabusarakam - Songkhia, TH
International Classification:
A61K 39/395, A61K 31/352, A61K 31/40, A61K 31/4418, A61K 31/405, A61K 31/47, A61K 31/505, A61K 31/616, A61K 31/4365, A61K 31/519, A61P 9/10, A61P 3/06, A61P 7/02
US Classification:
4241331, 514456, 514423, 514277, 514415, 514311, 514275, 514161, 514301, 5142621
Abstract:
Provided herein are methods of treating postangiplasty, in-stent restenosis or atherosclerosis in an individual in need of such treatment, comprising the step of administering to said individual an effective dose of morelloflavone with or with a effective dose of one or more of an HMG-CoA reductase inhibitor or a hypolipidemic agent or lipid-lowering agent or other lipid agent or lipid modulating agent or anti-atherosclerotic agent. Also provided are pharmaceutical compositions comprising a morelloflavone or pharmaceutical combinations comprising a morelloflavone and one of an HMG-CoA reductase inhibitor or a hypolipidemic agent or lipid-lowering agent or other lipid agent or lipid modulating agent or anti-atherosclerotic agent.